<DOC>
	<DOCNO>NCT00822094</DOCNO>
	<brief_summary>The study investigate CPX-351 ) effective standard intensive salvage AML treatment b ) tolerable standard intensive salvage treatment regimen . The study compare investigational product CPX-351 vs standard intensive salvage treatment first relapse AML patient .</brief_summary>
	<brief_title>Trial CPX-351 Adult Patients With First Relapse Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>This study randomize , open-label , parallel-arm , fixed-dose , standard therapy control Phase IIB trial . Study enrollment duration expect approximately 12-18 month . On entry , patient randomize receive either CPX-351 intensive first salvage treatment . Patients stratify balance likelihood obtain CR duration CR two arm .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Ability understand voluntarily sign informed consent form Age ≥18 ≤65 year time relapse Pathological confirmation relapse AML initial CR &gt; 1 month duration Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Able adhere study visit schedule protocol requirement Laboratory value fulfil follow : Serum creatinine &lt; 2.0 mg/dL Serum total bilirubin &lt; 2.0 mg/dL Serum alanine aminotransferase aspartate aminotransferase &lt; 3xULN Note : If elevate liver enzymes related disease ; contact medical monitor discus . Cardiac ejection fraction &gt; 50 % echocardiography MUGA scan All men woman must agree practice effective contraception study period 3 month afterward otherwise document infertile . Patients active second malignancy exclude . Patients second malignancy remission may eligible clinical evidence active disease , document imaging , tumor marker study , etc. , screen . Patients maintain longterm nonchemotherapy treatment , e.g. , hormonal therapy , eligible . In case , second malignancy nonchemotherapy treatment must interfere investigator ability assess safety efficacy study treatment Patients acute promyelocytic leukemia [ ( 15 ; 17 ) ] Total lifetime anthracycline exposure exceed equivalent 368 mg/m2 daunorubicin ( equivalent ) prior start study therapy Any serious medical condition , laboratory abnormality psychiatric illness would prevent obtain informed consent Administration antineoplastic therapy within 4 week therapy ; intend treat first relapse . In event rapidly proliferative disease use hydroxyurea permit 24 hour start study treatment Clinical evidence active CNS leukemia Patients history and/or current evidence myocardial impairment ( e.g . cardiomyopathy , ischemic heart disease , significant valvular dysfunction , hypertensive heart disease , congestive heart failure ) result New York Heart Association Class III IV stag Active uncontrolled infection . Patients bacterial infection receive treatment antibiotic may enter study afebrile hemodynamically stable &gt; 72 hr . Current evidence invasive fungal infection ( blood tissue culture ) ; active hepatitis C infection know HIV infection Hypersensitivity cytarabine , daunorubicin liposomal product History Wilson 's disease copperrelated disorder Patients history severe toxicity relate receive conventional dose cytarabine first line treatment ( approximately 100mg/m2/d &lt; 7 day ) exclude . Patients experience unacceptable toxicity receive high dose cytarabine ( approximately 3000mg/m2 6 dos ) treat regimen , could randomize treatment conventional dose cytarabine regimen risk major toxicity less . Woman pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Acute</keyword>
	<keyword>Myeloid</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Adult</keyword>
	<keyword>First</keyword>
	<keyword>Relapse</keyword>
	<keyword>AML</keyword>
	<keyword>Acute Myelogenous leukemia</keyword>
	<keyword>Leukemia , Myeloid</keyword>
	<keyword>Leukemia , Myeloid , Acute</keyword>
	<keyword>Acute myelocytic leukemia</keyword>
</DOC>